Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vycor Medical's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 41.05.
Vycor Medical's Days Inventory for the
three
months ended in Mar. 2026 was 185.22.
Vycor Medical's Days Payable for the
three
months ended in Mar. 2026 was 95.05.
Therefore, Vycor Medical's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 131.22.
Vycor Medical (OTCPK:VYCO) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vycor Medical Cash Conversion Cycle Related Terms
Vycor Medical Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Vycor Medical's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYCO vs AEMD, VTAK, ALURD: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Vycor Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vycor Medical Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vycor Medical's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vycor Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vycor Medical (VYCO) has a Cash Conversion Cycle of 131.22 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vycor Medical and its competitors.
Is Vycor Medical's Cash Conversion Cycle too high?
Vycor Medical's current Cash Conversion Cycle is 131.22. The Medical Devices & Instruments industry median Cash Conversion Cycle is 157.71. Vycor Medical's value of 131.22 is 16.8% below this industry median.
How does Vycor Medical's Cash Conversion Cycle compare to AEMD and VTAK?
Vycor Medical's Cash Conversion Cycle of 131.22 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. Vycor Medical's value of 131.22 is 16.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vycor Medical's current Cash Conversion Cycle of 131.22 is 16.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vycor Medical and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vycor Medical's current Cash Conversion Cycle is 131.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vycor Medical stock overvalued right now?
Based on GuruFocus' analysis, Vycor Medical (VYCO) is currently considered Possible Value Trap. The stock's GF Value™ is $0.12, compared to a current price of $0.07 — trading 42.5% below its estimated fair value. The current Cash Conversion Cycle is 131.22 and 16.8% below the Medical Devices & Instruments industry median of 157.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vycor Medical (VYCO), the current Cash Conversion Cycle is 131.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vycor Medical Inc provides the medical community with superior surgical and therapeutic solutions and operates two distinct business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. The company operates in two segments, Vycor Medical and NovaVision, with the majority of the revenue been derived from Vycor Medical segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYCO has been successfully added to your 
